APO Research
Talk to an analyst

APO RESEARCH · REPORT

IBS Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global IBS Treatment Market Outlook and Growth Opportunities 2026

20 December 2025216 pages

Choose your research edition.

Industry ResearchIBS Treatment Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal IBS Treatment Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal IBS Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IBS Treatment Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal IBS Treatment Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global IBS Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the IBS Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the IBS Treatment market include Takeda Pharmaceutical Company (Japan), Nestle (Switzerland), Novartis (Switzerland), Pfizer (U.S.), Synthetic Biologics (U.S.), Synergy Pharmaceuticals (U.S.), Sucampo Pharmaceuticals (U.S.), Sebela Pharmaceuticals (Ireland) and RedHill Biopharma (Israel), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global IBS Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IBS Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IBS Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global IBS Treatment market.

IBS Treatment Segment by Company

Takeda Pharmaceutical Company (Japan)

Nestle (Switzerland)

Novartis (Switzerland)

Pfizer (U.S.)

Synthetic Biologics (U.S.)

Synergy Pharmaceuticals (U.S.)

Sucampo Pharmaceuticals (U.S.)

Sebela Pharmaceuticals (Ireland)

RedHill Biopharma (Israel)

Protagonist Therapeutics (U.S.)

Probi (Sweden)

Lexicon Pharmaceuticals (U.S.)

Ironwood Pharmaceuticals (U.S.)

Ipsen (France)

Innovate Biopharmaceuticals (U.S.)

Bausch Health

AstraZeneca (U.K)

Astellas Pharma (Japan)

Ardelyx (U.S.)

Allergan (Ireland)

Alfasigma USA (Italy)

Abbott Laboratories (U.S.)

IBS Treatment Segment by Type

IBS-D

IBS-C

IBS-M

IBS Treatment Segment by Application

Hospitals

Clinics

Research Laboratories

IBS Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global IBS Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the IBS Treatment key companies, revenue, market share, and recent developments.

3. To split the IBS Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions IBS Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify IBS Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze IBS Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IBS Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global IBS Treatment industry.

Chapter 3: Detailed analysis of IBS Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of IBS Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of IBS Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. IBS Treatment Industry Trends Table 2. IBS Treatment Industry Drivers Table 3. IBS Treatment Industry Opportunities and Challenges Table 4. IBS Treatment Industry Restraints Table 5. Global IBS Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global IBS Treatment Revenue Share by Company (2021-2026) Table 7. Global IBS Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global IBS Treatment Key Company Manufacturing Base & Headquarters Table 9. Global IBS Treatment Company, Product Type & Application Table 10. Global IBS Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global IBS Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of IBS-D Table 15. Significant Companies of IBS-C Table 16. Significant Companies of IBS-M Table 17. Global IBS Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global IBS Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global IBS Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global IBS Treatment Sales Value Share by Type (2021-2026) Table 21. Global IBS Treatment Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Clinics Table 24. Significant Companies of Research Laboratories Table 25. Global IBS Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global IBS Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global IBS Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global IBS Treatment Sales Value Share by Application (2021-2026) Table 29. Global IBS Treatment Sales Value Share by Application (2027-2032) Table 30. Global IBS Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global IBS Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global IBS Treatment Sales Value Share by Region (2021-2026) Table 33. Global IBS Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global IBS Treatment Sales Value Share by Region (2027-2032) Table 35. Global IBS Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global IBS Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global IBS Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global IBS Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global IBS Treatment Sales Value Market Share by Country (2027-2032) Table 40. Takeda Pharmaceutical Company (Japan) Company Information Table 41. Takeda Pharmaceutical Company (Japan) Business Overview Table 42. Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Takeda Pharmaceutical Company (Japan) IBS Treatment Product Portfolio Table 44. Takeda Pharmaceutical Company (Japan) Recent Development Table 45. Nestle (Switzerland) Company Information Table 46. Nestle (Switzerland) Business Overview Table 47. Nestle (Switzerland) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Nestle (Switzerland) IBS Treatment Product Portfolio Table 49. Nestle (Switzerland) Recent Development Table 50. Novartis (Switzerland) Company Information Table 51. Novartis (Switzerland) Business Overview Table 52. Novartis (Switzerland) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis (Switzerland) IBS Treatment Product Portfolio Table 54. Novartis (Switzerland) Recent Development Table 55. Pfizer (U.S.) Company Information Table 56. Pfizer (U.S.) Business Overview Table 57. Pfizer (U.S.) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Pfizer (U.S.) IBS Treatment Product Portfolio Table 59. Pfizer (U.S.) Recent Development Table 60. Synthetic Biologics (U.S.) Company Information Table 61. Synthetic Biologics (U.S.) Business Overview Table 62. Synthetic Biologics (U.S.) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Synthetic Biologics (U.S.) IBS Treatment Product Portfolio Table 64. Synthetic Biologics (U.S.) Recent Development Table 65. Synergy Pharmaceuticals (U.S.) Company Information Table 66. Synergy Pharmaceuticals (U.S.) Business Overview Table 67. Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Synergy Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 69. Synergy Pharmaceuticals (U.S.) Recent Development Table 70. Sucampo Pharmaceuticals (U.S.) Company Information Table 71. Sucampo Pharmaceuticals (U.S.) Business Overview Table 72. Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 74. Sucampo Pharmaceuticals (U.S.) Recent Development Table 75. Sebela Pharmaceuticals (Ireland) Company Information Table 76. Sebela Pharmaceuticals (Ireland) Business Overview Table 77. Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sebela Pharmaceuticals (Ireland) IBS Treatment Product Portfolio Table 79. Sebela Pharmaceuticals (Ireland) Recent Development Table 80. RedHill Biopharma (Israel) Company Information Table 81. RedHill Biopharma (Israel) Business Overview Table 82. RedHill Biopharma (Israel) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. RedHill Biopharma (Israel) IBS Treatment Product Portfolio Table 84. RedHill Biopharma (Israel) Recent Development Table 85. Protagonist Therapeutics (U.S.) Company Information Table 86. Protagonist Therapeutics (U.S.) Business Overview Table 87. Protagonist Therapeutics (U.S.) IBS Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Protagonist Therapeutics (U.S.) IBS Treatment Product Portfolio Table 89. Protagonist Therapeutics (U.S.) Recent Development Table 90. Probi (Sweden) Company Information Table 91. Probi (Sweden) Business Overview Table 92. Probi (Sweden) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Probi (Sweden) IBS Treatment Product Portfolio Table 94. Probi (Sweden) Recent Development Table 95. Lexicon Pharmaceuticals (U.S.) Company Information Table 96. Lexicon Pharmaceuticals (U.S.) Business Overview Table 97. Lexicon Pharmaceuticals (U.S.) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 99. Lexicon Pharmaceuticals (U.S.) Recent Development Table 100. Ironwood Pharmaceuticals (U.S.) Company Information Table 101. Ironwood Pharmaceuticals (U.S.) Business Overview Table 102. Ironwood Pharmaceuticals (U.S.) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 104. Ironwood Pharmaceuticals (U.S.) Recent Development Table 105. Ipsen (France) Company Information Table 106. Ipsen (France) Business Overview Table 107. Ipsen (France) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Ipsen (France) IBS Treatment Product Portfolio Table 109. Ipsen (France) Recent Development Table 110. Innovate Biopharmaceuticals (U.S.) Company Information Table 111. Innovate Biopharmaceuticals (U.S.) Business Overview Table 112. Innovate Biopharmaceuticals (U.S.) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 114. Innovate Biopharmaceuticals (U.S.) Recent Development Table 115. Bausch Health Company Information Table 116. Bausch Health Business Overview Table 117. Bausch Health IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Bausch Health IBS Treatment Product Portfolio Table 119. Bausch Health Recent Development Table 120. AstraZeneca (U.K) Company Information Table 121. AstraZeneca (U.K) Business Overview Table 122. AstraZeneca (U.K) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. AstraZeneca (U.K) IBS Treatment Product Portfolio Table 124. AstraZeneca (U.K) Recent Development Table 125. Astellas Pharma (Japan) Company Information Table 126. Astellas Pharma (Japan) Business Overview Table 127. Astellas Pharma (Japan) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Astellas Pharma (Japan) IBS Treatment Product Portfolio Table 129. Astellas Pharma (Japan) Recent Development Table 130. Ardelyx (U.S.) Company Information Table 131. Ardelyx (U.S.) Business Overview Table 132. Ardelyx (U.S.) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Ardelyx (U.S.) IBS Treatment Product Portfolio Table 134. Ardelyx (U.S.) Recent Development Table 135. Allergan (Ireland) Company Information Table 136. Allergan (Ireland) Business Overview Table 137. Allergan (Ireland) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Allergan (Ireland) IBS Treatment Product Portfolio Table 139. Allergan (Ireland) Recent Development Table 140. Alfasigma USA (Italy) Company Information Table 141. Alfasigma USA (Italy) Business Overview Table 142. Alfasigma USA (Italy) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Alfasigma USA (Italy) IBS Treatment Product Portfolio Table 144. Alfasigma USA (Italy) Recent Development Table 145. Abbott Laboratories (U.S.) Company Information Table 146. Abbott Laboratories (U.S.) Business Overview Table 147. Abbott Laboratories (U.S.) IBS Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Abbott Laboratories (U.S.) IBS Treatment Product Portfolio Table 149. Abbott Laboratories (U.S.) Recent Development Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. IBS Treatment Product Image Figure 2. Global IBS Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global IBS Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. IBS-D Image Figure 8. IBS-C Image Figure 9. IBS-M Image Figure 10. Global IBS Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global IBS Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global IBS Treatment Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Clinics Image Figure 15. Research Laboratories Image Figure 16. Global IBS Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global IBS Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global IBS Treatment Sales Value Share by Application (2021-2032) Figure 19. Global IBS Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global IBS Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America IBS Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America IBS Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe IBS Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe IBS Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific IBS Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific IBS Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America IBS Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America IBS Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa IBS Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa IBS Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt IBS Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt IBS Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt IBS Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • IBS-D
  • IBS-C
  • IBS-M
Applications
  • Hospitals
  • Clinics
  • Research Laboratories
Companies covered
  • Takeda Pharmaceutical Company (Japan)
  • Nestle (Switzerland)
  • Novartis (Switzerland)
  • Pfizer (U.S.)
  • Synthetic Biologics (U.S.)
  • Synergy Pharmaceuticals (U.S.)
  • Sucampo Pharmaceuticals (U.S.)
  • Sebela Pharmaceuticals (Ireland)
  • RedHill Biopharma (Israel)
  • Protagonist Therapeutics (U.S.)
  • Probi (Sweden)
  • Lexicon Pharmaceuticals (U.S.)
  • Ironwood Pharmaceuticals (U.S.)
  • Ipsen (France)
  • Innovate Biopharmaceuticals (U.S.)
  • Bausch Health
  • AstraZeneca (U.K)
  • Astellas Pharma (Japan)
  • Ardelyx (U.S.)
  • Allergan (Ireland)
  • Alfasigma USA (Italy)
  • Abbott Laboratories (U.S.)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global IBS Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global IBS Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 IBS Treatment Market Dynamics
  1. 2.1 IBS Treatment Industry Trends
  2. 2.2 IBS Treatment Industry Drivers
  3. 2.3 IBS Treatment Industry Opportunities and Challenges
  4. 2.4 IBS Treatment Industry Restraints
3 IBS Treatment Market by Company
  1. 3.1 Global IBS Treatment Company Revenue Ranking in 2025
  2. 3.2 Global IBS Treatment Revenue by Company (2021-2026)
  3. 3.3 Global IBS Treatment Company Ranking (2024-2026)
  4. 3.4 Global IBS Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global IBS Treatment Company Product Type and Application
  6. 3.6 Global IBS Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global IBS Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 IBS Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 IBS Treatment Market by Type
  1. 4.1 IBS Treatment Type Introduction
  2. 4.1.1 IBS-D
  3. 4.1.2 IBS-C
  4. 4.1.3 IBS-M
  5. 4.2 Global IBS Treatment Sales Value by Type
  6. 4.2.1 Global IBS Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global IBS Treatment Sales Value by Type (2021-2032)
  8. 4.2.3 Global IBS Treatment Sales Value Share by Type (2021-2032)
5 IBS Treatment Market by Application
  1. 5.1 IBS Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Research Laboratories
  5. 5.2 Global IBS Treatment Sales Value by Application
  6. 5.2.1 Global IBS Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IBS Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global IBS Treatment Sales Value Share by Application (2021-2032)
6 IBS Treatment Regional Value Analysis
  1. 6.1 Global IBS Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IBS Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global IBS Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global IBS Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America IBS Treatment Sales Value (2021-2032)
  7. 6.3.2 North America IBS Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe IBS Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe IBS Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific IBS Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific IBS Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America IBS Treatment Sales Value (2021-2032)
  16. 6.6.2 South America IBS Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa IBS Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa IBS Treatment Sales Value Share by Country, 2025 VS 2032
7 IBS Treatment Country-level Value Analysis
  1. 7.1 Global IBS Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global IBS Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global IBS Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global IBS Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA IBS Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA IBS Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA IBS Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada IBS Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada IBS Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada IBS Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico IBS Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico IBS Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico IBS Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany IBS Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany IBS Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany IBS Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France IBS Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France IBS Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France IBS Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. IBS Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. IBS Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. IBS Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy IBS Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy IBS Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy IBS Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain IBS Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain IBS Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain IBS Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia IBS Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia IBS Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia IBS Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands IBS Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands IBS Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands IBS Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries IBS Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries IBS Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries IBS Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China IBS Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China IBS Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China IBS Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan IBS Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan IBS Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan IBS Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea IBS Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea IBS Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea IBS Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India IBS Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India IBS Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India IBS Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia IBS Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia IBS Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia IBS Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia IBS Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia IBS Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia IBS Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil IBS Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil IBS Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil IBS Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina IBS Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina IBS Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina IBS Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile IBS Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile IBS Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile IBS Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia IBS Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia IBS Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia IBS Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru IBS Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru IBS Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru IBS Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia IBS Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia IBS Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia IBS Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel IBS Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel IBS Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel IBS Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE IBS Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE IBS Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE IBS Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey IBS Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey IBS Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey IBS Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran IBS Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran IBS Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran IBS Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt IBS Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt IBS Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt IBS Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company (Japan)
  2. 8.1.1 Takeda Pharmaceutical Company (Japan) Company Information
  3. 8.1.2 Takeda Pharmaceutical Company (Japan) Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company (Japan) IBS Treatment Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company (Japan) Recent Developments
  7. 8.2 Nestle (Switzerland)
  8. 8.2.1 Nestle (Switzerland) Company Information
  9. 8.2.2 Nestle (Switzerland) Business Overview
  10. 8.2.3 Nestle (Switzerland) IBS Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Nestle (Switzerland) IBS Treatment Product Portfolio
  12. 8.2.5 Nestle (Switzerland) Recent Developments
  13. 8.3 Novartis (Switzerland)
  14. 8.3.1 Novartis (Switzerland) Company Information
  15. 8.3.2 Novartis (Switzerland) Business Overview
  16. 8.3.3 Novartis (Switzerland) IBS Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis (Switzerland) IBS Treatment Product Portfolio
  18. 8.3.5 Novartis (Switzerland) Recent Developments
  19. 8.4 Pfizer (U.S.)
  20. 8.4.1 Pfizer (U.S.) Company Information
  21. 8.4.2 Pfizer (U.S.) Business Overview
  22. 8.4.3 Pfizer (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer (U.S.) IBS Treatment Product Portfolio
  24. 8.4.5 Pfizer (U.S.) Recent Developments
  25. 8.5 Synthetic Biologics (U.S.)
  26. 8.5.1 Synthetic Biologics (U.S.) Company Information
  27. 8.5.2 Synthetic Biologics (U.S.) Business Overview
  28. 8.5.3 Synthetic Biologics (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Synthetic Biologics (U.S.) IBS Treatment Product Portfolio
  30. 8.5.5 Synthetic Biologics (U.S.) Recent Developments
  31. 8.6 Synergy Pharmaceuticals (U.S.)
  32. 8.6.1 Synergy Pharmaceuticals (U.S.) Company Information
  33. 8.6.2 Synergy Pharmaceuticals (U.S.) Business Overview
  34. 8.6.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Synergy Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  36. 8.6.5 Synergy Pharmaceuticals (U.S.) Recent Developments
  37. 8.7 Sucampo Pharmaceuticals (U.S.)
  38. 8.7.1 Sucampo Pharmaceuticals (U.S.) Company Information
  39. 8.7.2 Sucampo Pharmaceuticals (U.S.) Business Overview
  40. 8.7.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  42. 8.7.5 Sucampo Pharmaceuticals (U.S.) Recent Developments
  43. 8.8 Sebela Pharmaceuticals (Ireland)
  44. 8.8.1 Sebela Pharmaceuticals (Ireland) Company Information
  45. 8.8.2 Sebela Pharmaceuticals (Ireland) Business Overview
  46. 8.8.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sebela Pharmaceuticals (Ireland) IBS Treatment Product Portfolio
  48. 8.8.5 Sebela Pharmaceuticals (Ireland) Recent Developments
  49. 8.9 RedHill Biopharma (Israel)
  50. 8.9.1 RedHill Biopharma (Israel) Company Information
  51. 8.9.2 RedHill Biopharma (Israel) Business Overview
  52. 8.9.3 RedHill Biopharma (Israel) IBS Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 RedHill Biopharma (Israel) IBS Treatment Product Portfolio
  54. 8.9.5 RedHill Biopharma (Israel) Recent Developments
  55. 8.10 Protagonist Therapeutics (U.S.)
  56. 8.10.1 Protagonist Therapeutics (U.S.) Company Information
  57. 8.10.2 Protagonist Therapeutics (U.S.) Business Overview
  58. 8.10.3 Protagonist Therapeutics (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Protagonist Therapeutics (U.S.) IBS Treatment Product Portfolio
  60. 8.10.5 Protagonist Therapeutics (U.S.) Recent Developments
  61. 8.11 Probi (Sweden)
  62. 8.11.1 Probi (Sweden) Company Information
  63. 8.11.2 Probi (Sweden) Business Overview
  64. 8.11.3 Probi (Sweden) IBS Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Probi (Sweden) IBS Treatment Product Portfolio
  66. 8.11.5 Probi (Sweden) Recent Developments
  67. 8.12 Lexicon Pharmaceuticals (U.S.)
  68. 8.12.1 Lexicon Pharmaceuticals (U.S.) Company Information
  69. 8.12.2 Lexicon Pharmaceuticals (U.S.) Business Overview
  70. 8.12.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  72. 8.12.5 Lexicon Pharmaceuticals (U.S.) Recent Developments
  73. 8.13 Ironwood Pharmaceuticals (U.S.)
  74. 8.13.1 Ironwood Pharmaceuticals (U.S.) Company Information
  75. 8.13.2 Ironwood Pharmaceuticals (U.S.) Business Overview
  76. 8.13.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  78. 8.13.5 Ironwood Pharmaceuticals (U.S.) Recent Developments
  79. 8.14 Ipsen (France)
  80. 8.14.1 Ipsen (France) Company Information
  81. 8.14.2 Ipsen (France) Business Overview
  82. 8.14.3 Ipsen (France) IBS Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Ipsen (France) IBS Treatment Product Portfolio
  84. 8.14.5 Ipsen (France) Recent Developments
  85. 8.15 Innovate Biopharmaceuticals (U.S.)
  86. 8.15.1 Innovate Biopharmaceuticals (U.S.) Company Information
  87. 8.15.2 Innovate Biopharmaceuticals (U.S.) Business Overview
  88. 8.15.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Portfolio
  90. 8.15.5 Innovate Biopharmaceuticals (U.S.) Recent Developments
  91. 8.16 Bausch Health
  92. 8.16.1 Bausch Health Company Information
  93. 8.16.2 Bausch Health Business Overview
  94. 8.16.3 Bausch Health IBS Treatment Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bausch Health IBS Treatment Product Portfolio
  96. 8.16.5 Bausch Health Recent Developments
  97. 8.17 AstraZeneca (U.K)
  98. 8.17.1 AstraZeneca (U.K) Company Information
  99. 8.17.2 AstraZeneca (U.K) Business Overview
  100. 8.17.3 AstraZeneca (U.K) IBS Treatment Revenue and Gross Margin (2021-2026)
  101. 8.17.4 AstraZeneca (U.K) IBS Treatment Product Portfolio
  102. 8.17.5 AstraZeneca (U.K) Recent Developments
  103. 8.18 Astellas Pharma (Japan)
  104. 8.18.1 Astellas Pharma (Japan) Company Information
  105. 8.18.2 Astellas Pharma (Japan) Business Overview
  106. 8.18.3 Astellas Pharma (Japan) IBS Treatment Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Astellas Pharma (Japan) IBS Treatment Product Portfolio
  108. 8.18.5 Astellas Pharma (Japan) Recent Developments
  109. 8.19 Ardelyx (U.S.)
  110. 8.19.1 Ardelyx (U.S.) Company Information
  111. 8.19.2 Ardelyx (U.S.) Business Overview
  112. 8.19.3 Ardelyx (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Ardelyx (U.S.) IBS Treatment Product Portfolio
  114. 8.19.5 Ardelyx (U.S.) Recent Developments
  115. 8.20 Allergan (Ireland)
  116. 8.20.1 Allergan (Ireland) Company Information
  117. 8.20.2 Allergan (Ireland) Business Overview
  118. 8.20.3 Allergan (Ireland) IBS Treatment Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Allergan (Ireland) IBS Treatment Product Portfolio
  120. 8.20.5 Allergan (Ireland) Recent Developments
  121. 8.21 Alfasigma USA (Italy)
  122. 8.21.1 Alfasigma USA (Italy) Company Information
  123. 8.21.2 Alfasigma USA (Italy) Business Overview
  124. 8.21.3 Alfasigma USA (Italy) IBS Treatment Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Alfasigma USA (Italy) IBS Treatment Product Portfolio
  126. 8.21.5 Alfasigma USA (Italy) Recent Developments
  127. 8.22 Abbott Laboratories (U.S.)
  128. 8.22.1 Abbott Laboratories (U.S.) Company Information
  129. 8.22.2 Abbott Laboratories (U.S.) Business Overview
  130. 8.22.3 Abbott Laboratories (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Abbott Laboratories (U.S.) IBS Treatment Product Portfolio
  132. 8.22.5 Abbott Laboratories (U.S.) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst